A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma
A. K. Weiner, A. B. Radaoui, M. Tsang, D. Martinez, S. Sidoli, K. L. Conkrite, A. Delaidelli, A. Modi, J. L. Rokita, K. Patel, M. V. Lane, B. Zhang, C. Zhong, B. Ennis, D. P. Miller, , S. J. Diskin
This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.
bioRxiv · Dec 6, 2023 · PreprintCancer Biology